PLEDGE NOW
Here and Now with Robin Young and Jeremy Hobson
Public radio's live
midday news program
With sponsorship from
Mathworks - Accelerating the pace of engineering and science
Accelerating the pace
of engineering and science
Wednesday, January 23, 2013

Expert: Flu Vaccine Developers Must Start From Scratch

Vials of flu vaccine are displayed at the Whittier Street Health Center in Boston, Mass., in January 2013. (Charles Krupa/AP)

Vials of flu vaccine are displayed at the Whittier Street Health Center in Boston, Mass., in January 2013. (Charles Krupa/AP)

This year’s flu season has been particularly nasty, reaching “epidemic” territory, according to the Centers for Disease Control and Prevention. Experts are predicting the flu could claim 36,000 lives this year.

The current shot is only about 62 percent effective, so pharmaceutical companies are working to improve the vaccine.

Some ideas include creating a vaccine that would cover more strains of the flu, developing a “universal” shot that would last five to ten years (instead of one) and using genetic sequencing to analyze strains so that researchers can better predict how the flu will evolve each year.

But Dr. Michael Osterholm, a University of Minnesota infectious disease expert, said none of those innovations will make much of a difference because the fundamental building block of the vaccine needs an update.

Old Antigens

Osterholm says the antigen used in vaccines, which causes the immune system to create antibodies to fight influenza, is the same one that’s been used since the 1940s.

“The problem we’re having today is that you can’t really amp that up much without changing it completely,” Osterholm said. “It would be like putting a 1940s transmission in a 2012 car.”

Osterholm says there are two major barriers to getting new game-changing vaccines to market. First, he says the public believes the current vaccine is good enough, so there’s no urgency to develop a brand new vaccine.

The second reason has to do with money.

Financial Concerns

“The vast majority of the modern technologies are in the hands of start-up companies that are literally hanging on by the skin of their teeth,” Osterholm said.

He estimates it could cost up to $1 billion to develop a new vaccines, but the investment community isn’t interested in a risky product that might never make it past the regulatory process.

“Remember, pharmaceutical companies are not philanthropic organizations,” Osterholm said.

If new vaccines do come to market, consumers might have to pay more for their flu shot, but they’d be getting a better return on their investment, because the shot would actually work.

In the meantime, Americans will have to rely on a vaccine that is only 62 percent effective across the board, and much less effective for older people.

“My prediction is that by the end of the year, we are only going to see marginal, if any benefit for people over age 65, yet that’s where the most severe disease and the deaths are occurring,” Osterholm said.

Guest:


Please follow our community rules when engaging in comment discussion on this site.
Robin and Jeremy

Robin Young and Jeremy Hobson host Here & Now, a live two-hour production of NPR and WBUR Boston.

July 30 33 Comments

Oxford Conservationist Talks About 7 Years Of Tracking Cecil

The 13-year-old lion was not only a tourist favorite, but also, a research animal. The beloved lion was being studied by the Oxford University Conservation Unit.

July 30 23 Comments

NAACP To Begin 860-Mile ‘Journey For Justice’ March

The march, which will travel from Selma, Ala. to Washington, seeks to highlight vulnerable communities subject to regressive voting rights.

July 29 2 Comments

Garden-Inspired Cooking With Kathy Gunst

We visit our resident chef's garden in Maine, make gazpacho and get a recipe for a plum tart with hazelnut crust.

July 29 641 Comments

Two Sides Of The GMO Debate

We moderate a debate over a bill that would bar states from forcing food manufacturers to label genetically modified foods.